Cytophagic histiocytic panniculitis: Difference between revisions
←Created page with 'Cytophagic Histiocytic Panniculitis (CHP) was first described in 1980 by Winkelmann as a chronic histiocytic disease of the subcutaneous adipose tissue, which is ch…' |
m tag, added uncategorised tag, added deadend tag, added w using [[Project:AutoWikiBrowser|AWB |
||
| Line 1: | Line 1: | ||
{{Wikify|date=March 2009}} |
|||
| ⚫ | Cytophagic Histiocytic Panniculitis (CHP) was first described in 1980 by Winkelmann as a chronic histiocytic disease of the subcutaneous adipose tissue, which is characterized clinically by tender erythematous nodules, recurrent high fever, malaise, jaundice, organomegaly, serosal effusions, pancytopenia, hepatic dysfunction and coagulatory abnormalities. [1] CHP may occur either isolated or as part of cutaneous manifestations of Hemophagocytic Syndrome (HPS). [2] CHP is a rare and often fatal form of panniculitis with multisystem involvement. But it can also present in a benign form involving only the subcutaneous tissue, thus having a broad clinical spectrum. |
||
{{deadend|date=March 2009}} |
|||
| ⚫ | Cytophagic Histiocytic Panniculitis (CHP) was first described in 1980 by Winkelmann as a chronic histiocytic disease of the subcutaneous adipose tissue, which is characterized clinically by tender erythematous nodules, recurrent high fever, malaise, jaundice, organomegaly, serosal effusions, pancytopenia, hepatic dysfunction and coagulatory abnormalities. [1] CHP may occur either isolated or as part of cutaneous manifestations of Hemophagocytic Syndrome (HPS). [2] CHP is a rare and often fatal form of panniculitis with multisystem involvement. But it can also present in a benign form involving only the subcutaneous tissue, thus having a broad clinical spectrum. |
||
References |
References |
||
1. Winkelmann RK, Bowie EJ. Hemorrhagic diathesis associated with benign histiocytic cytophagic panniculitis and systemic histiocytosis. Arch Intern Med.1980; 140: 1460-3 |
1. Winkelmann RK, Bowie EJ. Hemorrhagic diathesis associated with benign histiocytic cytophagic panniculitis and systemic histiocytosis. Arch Intern Med.1980; 140: 1460-3 |
||
2. Smith K J, Skeleton H J, Yeagre J, Angritt P, Wagner K, James W. D., Giblin W. J., Lupton G. P. Cutaneous histopathological, immunohistochemical, and clinical manifestations inpatients with hemophagocytic syndrome. Military Medical Consortium for Applied Retroviral Research (MMCARR). Arch Dermatol 1992; 128: 193-200 |
2. Smith K J, Skeleton H J, Yeagre J, Angritt P, Wagner K, James W. D., Giblin W. J., Lupton G. P. Cutaneous histopathological, immunohistochemical, and clinical manifestations inpatients with hemophagocytic syndrome. Military Medical Consortium for Applied Retroviral Research (MMCARR). Arch Dermatol 1992; 128: 193-200 |
||
{{Uncategorized|date=March 2009}} |
|||
Revision as of 17:35, 2 March 2009
 | Template:Wikify is deprecated. Please use a more specific cleanup template as listed in the documentation. |
 | This article has no links to other Wikipedia articles. (March 2009) |
Cytophagic Histiocytic Panniculitis (CHP) was first described in 1980 by Winkelmann as a chronic histiocytic disease of the subcutaneous adipose tissue, which is characterized clinically by tender erythematous nodules, recurrent high fever, malaise, jaundice, organomegaly, serosal effusions, pancytopenia, hepatic dysfunction and coagulatory abnormalities. [1] CHP may occur either isolated or as part of cutaneous manifestations of Hemophagocytic Syndrome (HPS). [2] CHP is a rare and often fatal form of panniculitis with multisystem involvement. But it can also present in a benign form involving only the subcutaneous tissue, thus having a broad clinical spectrum.
References 1. Winkelmann RK, Bowie EJ. Hemorrhagic diathesis associated with benign histiocytic cytophagic panniculitis and systemic histiocytosis. Arch Intern Med.1980; 140: 1460-3 2. Smith K J, Skeleton H J, Yeagre J, Angritt P, Wagner K, James W. D., Giblin W. J., Lupton G. P. Cutaneous histopathological, immunohistochemical, and clinical manifestations inpatients with hemophagocytic syndrome. Military Medical Consortium for Applied Retroviral Research (MMCARR). Arch Dermatol 1992; 128: 193-200
 | This redirect has not been added to any content categories. Please help out by adding categories to it so that it can be listed with similar redirects. (March 2009) |